Update on biosimilars of granulocyte colony-stimulating factor: when no news is good news
With the approval of the first biosimilar granulocyte colony-stimulating factor (G-CSF), biosimilars - copies of therapeutic biologicals whose patent protection has expired - have finally reached the US healthcare market. Its advent is an occasion for a closer look at recent insights into biosimilar...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2016
|
| In: |
Current opinion in hematology
Year: 2016, Jahrgang: 23, Heft: 1, Pages: 61-66 |
| ISSN: | 1531-7048 |
| DOI: | 10.1097/MOH.0000000000000204 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1097/MOH.0000000000000204 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/co-hematology/fulltext/2016/01000/Update_on_biosimilars_of_granulocyte.11.aspx 
|
| Verfasserangaben: | Miriam Schulz and Halvard Bonig |
| Zusammenfassung: | With the approval of the first biosimilar granulocyte colony-stimulating factor (G-CSF), biosimilars - copies of therapeutic biologicals whose patent protection has expired - have finally reached the US healthcare market. Its advent is an occasion for a closer look at recent insights into biosimilar G-CSF and an attempt at prognosticating the future (future role) of biosimilars in general. |
|---|---|
| Beschreibung: | Gesehen am 26.05.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1531-7048 |
| DOI: | 10.1097/MOH.0000000000000204 |